Palisades Therapeutics Highlights a Shared Inflammatory Mechanism Across Chronic Diseases in Frontiers in Pharmacology

PT150 clinical experience & next-generation PT157 research support exploration of selective glucocorticoid receptor modulation across diverse therapeutic areas

CLIFFSIDE PARK, NJ, UNITED STATES, October 19, 2026 /EINPresswire.com/ — Pop Test Oncology LLC, dba Palisades Therapeutics, announces the publication of a peer-reviewed Perspective in Frontiers in Pharmacology examining glucocorticoid receptor (GR) modulation as a host-directed strategy for inflammatory priming across chronic disease states.

Publication: Frontiers in Pharmacology | Perspective | DOI / article link: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1931270/full

The Perspective, “Glucocorticoid Receptor Modulation as a Host-Directed Strategy for Inflammatory Priming Across Chronic Disease States,” brings together research spanning molecular signaling, transcriptomics, cellular systems, animal models, and early human investigations. Its central proposition is that persistent stress-axis and inflammatory dysregulation may represent a shared biological process across otherwise distinct disorders, not that one drug has been proven to treat them all.

The Perspective encompasses investigators from Colorado State University, Baylor College of Medicine, the University of Kentucky, Medical University of South Carolina, and the Icahn School of Medicine at Mount Sinai. Seven complementary experimental platforms support a testable hypothesis: dysregulated GR signaling may be a shared upstream contributor to inflammatory priming across otherwise distinct diagnoses.

Different diseases can have very different causes yet share inflammatory conditions that make recovery more difficult. Our objective is to investigate whether selective modulation of that underlying biology can help restore a more favorable environment for the body—and for disease-directed therapies—to work.

WHY THIS MATTERS
Chronic inflammatory priming can involve GR signaling, NF-κB-associated networks, and altered neuroimmune responses. The Perspective explores whether selectively modulating these pathways—rather than broadly suppressing immunity—could influence disease persistence and progression. Areas discussed include neuropsychiatric and addictive disorders, neurodegeneration, metabolic dysfunction, post-infectious syndromes, and selected cancers. These remain distinct development opportunities with differing levels of evidence.

THE STRATEGIC INSIGHT: TARGET THE UPSTREAM INFLAMMATORY STATE
Across post-traumatic stress disorder (PTSD), alcohol use disorder (AUD), Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), obesity, glioblastoma, pancreatic ductal adenocarcinoma, and post-viral syndromes including long COVID, the Perspective explores a common stress–inflammation framework. HPA-axis dysregulation and altered GR signaling may promote microglial priming, NF-κB-associated transcription, COX-2 activity, and persistent inflammatory amplification. The proposed opportunity is to modulate this upstream state rather than focus exclusively on downstream disease manifestations.

“What makes these findings particularly compelling is the convergence of evidence across seven distinct experimental platforms, each pointing toward a shared upstream mechanism of inflammatory dysregulation. Rather than treating chronic diseases solely through their downstream manifestations, our research suggests that modulating glucocorticoid receptor signaling may help restore inflammatory balance while preserving essential host-defense and repair pathways. This provides a scientifically grounded framework for investigating PT150 and PT157 across multiple disease states and identifying the patients most likely to benefit.”
— Richard (Ric) Slayden, PhD, Perspective co-author

FROM CLINICAL EXPERIENCE TO NEXT-GENERATION RESEARCH
PT150, an orally administered clinical-stage GR modulator, provides the platform’s human pharmacology foundation. It has extensive prior human exposure, CNS penetration, and clinical development that includes Phase 2 programs in alcohol use disorder (AUD) funded by the National Institutes of Health (NIH) and a post-traumatic stress disorder (PTSD) study supported by the U.S. Department of Defense.

PT157, a structurally related next-generation dimer, adds preclinical evidence of potentially greater potency. PT157 showed an approximately twofold mean molar potency advantage across measured endpoints. Additional transcriptomic and protein-signaling studies identify overlapping stress, inflammatory, metabolic, and survival networks.

A POTENTIAL COMPLEMENT TO DISEASE-DIRECTED THERAPIES
Palisades is exploring whether regulating inflammatory priming could complement treatments targeting a disease’s specific cause or pathology. The importance of this publication is the scientific framework it offers. It gives researchers and potential partners a focused rationale for deciding where this biology, supported by our existing clinical and preclinical evidence, deserves further investigation.

ABOUT PALISADES THERAPEUTICS
Pop Test Oncology LLC dba Palisades Therapeutics develops small-molecule therapeutics with programs spanning neuropsychiatric, inflammatory, and other disease-relevant biology. The company collaborates with academic and clinical investigators on translational research and clinical development.

Randi Altschul
Pop Test Oncology/Palisades Therapeutics
+1 201-943-3770
Visit us on social media:
LinkedIn

Media gallery